Related Experiment Video
Updated: Jul 29, 2026

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
Extracorporeal irradiation for malignant bone tumors
1Department of Radiation Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. ahong@radonc.rpa.cs.nsw.gov.au
Extracorporeal irradiation (ECI) offers promising short-term oncologic and orthopedic outcomes for primary malignant bone tumors. This limb-sparing technique shows good functional results in selected patients.
Area of Science:
- Orthopedic Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Extracorporeal irradiation (ECI) is a selective technique for managing primary malignant bone tumors.
- Since 1996, ECI has been employed, necessitating reporting of its techniques and outcomes.
Observation:
- Sixteen patients with primary malignant bone tumors (Ewing's sarcoma, osteosarcoma, chondrosarcoma) underwent ECI between 1996 and 2000.
- Tumor-bearing bone was resected after induction chemotherapy, irradiated extracorporeally (50 Gy), and reimplanted.
- Irradiation utilized either a linear accelerator or a blood product irradiator.
Findings:
- At a median follow-up of 19.5 months, no local recurrences or graft failures were observed.
- One patient required amputation due to chronic osteomyelitis.
- Functional outcomes were graded as good to excellent in 10 patients with over 18 months of follow-up.
Implications:
- ECI demonstrates encouraging short-term oncologic and orthopedic results for limb-sparing surgery in select patients.
- This technique is a viable alternative for reconstruction in primary malignant bone tumors.
- Long-term outcomes require careful assessment within a multidisciplinary setting.
More Related Videos
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
04:11A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
Published on: June 9, 2026